Inside TCG Labs Soleil’s $400M Bet on Focused Biotech
On 24 July 2025, TCG Labs Soleil, the biotech venture‑studio launched under The Column Group umbrella, quietly unveiled a second $400 million fund, matching its inaugural raise in 2024. That rightly triggered headlines—but what matters far more is how the firm is deploying capital. Its strategy: build dozens of micro‑startups, each centered on a single therapeutic asset, develop it through proof‑of‑concept, and exit swiftly. The implication: a subtle but fundamental shift in how biotech innovation—and venture capital—operates.
Why Even Well‑Seasoned Investors Should Lean In
The biotech industry has long revolved around platform plays—companies that carry multiple drug candidates,
